Email this article Atopic dermatitis: the role of care products in common dermatosis in pediatric practice
- Authors: Sakaniya L.R.1, Smolkina O.I.1,2, Korsunskaya I.M.1, Geppe N.A.3, Soboleva V.A.3,4
-
Affiliations:
- Center for Theoretical Problems of Physico-Chemical Pharmacology of the Russian Academy of Sciences
- LLC “Scientific and Clinical Consulting Center of Allergology and Immunology”
- Sechenov First Moscow State Medical University (Sechenov University)
- Mechnikov Research Institute of Vaccines and Sera
- Issue: No 1 (2024)
- Pages: 25-29
- Section: Articles
- URL: https://pediatria.orscience.ru/2658-6630/article/view/633323
- DOI: https://doi.org/10.26442/26586630.2024.1.202752
- ID: 633323
Cite item
Full Text
Abstract
Background. Atopic dermatitis (AD) is one of the most common skin disorders in pediatric practice. In AD, the barrier function of the skin and moisturizing factors are impaired, which requires using specialized care products. Therefore, healthcare professionals should be aware of effective and safe products that can be used in children.
Aim. To evaluate the clinical efficacy of LA-KRY cosmetics.
Materials and methods. The study included 39 patients with AD and 26 patients with allergic/contact dermatitis aged 0-7 years. In some children, skin corneometric indices (SCI) (humidity and oiliness) were measured before using care products and 14 and 30 days after the start of their use to assess their effectiveness. In the remaining patients, the clinical manifestations of skin disorders were assessed visually without instrumental methods.
Results. SCI improvement was observed after 14 days of using LA-KRY products and significantly improved by the end of month 1. Minimization of dryness and itching of the skin occurred by days 3-5, and clinical manifestations resolved by days 14-30 (depending on the nosology).
Conclusion. LA-KRY have shown their effectiveness in children with several dermatoses associated with skin barrier disruption, dryness, and itching; in particular, they help reduce inflammation and discomfort and normalize SCI.
Full Text
About the authors
Luiza R. Sakaniya
Center for Theoretical Problems of Physico-Chemical Pharmacology of the Russian Academy of Sciences
Email: marykor@bk.ru
ORCID iD: 0000-0003-2027-5987
Cand. Sci. (Med.)
Russian Federation, MoscowOlga Iu. Smolkina
Center for Theoretical Problems of Physico-Chemical Pharmacology of the Russian Academy of Sciences; LLC “Scientific and Clinical Consulting Center of Allergology and Immunology”
Email: marykor@bk.ru
ORCID iD: 0000-0002-3235-6461
Res. Assist., dermatovenerologist
Russian Federation, Moscow; MoscowIrina M. Korsunskaya
Center for Theoretical Problems of Physico-Chemical Pharmacology of the Russian Academy of Sciences
Author for correspondence.
Email: marykor@bk.ru
ORCID iD: 0000-0002-6583-0318
Sci. (Med.), Prof.
Russian Federation, MoscowNatalia A. Geppe
Sechenov First Moscow State Medical University (Sechenov University)
Email: marykor@bk.ru
ORCID iD: 0000-0003-0547-3686
Sci. (Med.), Prof.
Russian Federation, MoscowVictoria A. Soboleva
Sechenov First Moscow State Medical University (Sechenov University); Mechnikov Research Institute of Vaccines and Sera
Email: marykor@bk.ru
ORCID iD: 0000-0003-1758-5909
Cand. Sci. (Med.)
Russian Federation, Moscow; MoscowReferences
- Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013;24(5):476-86. doi: 10.1111/pai.12095
- Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl. 1):8-16. doi: 10.1159/000370220
- Yang EJ, Sekhon S, Sanchez IM, et al. Recent Developments in Atopic Dermatitis. Pediatrics. 2018;142(4). doi: 10.1542/peds.2018-1102
- Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30(1):35-9. doi: 10.1016/s0190-9622(94)70004-4
- Thamm R, Poethko-Müller C, Hüther A, Thamm M. Allergische Erkrankungen bei Kindern und Jugendlichen in Deutschland – Querschnittergebnisse aus KiGGS Welle 2 und Trends. J Health Monit. 2018;3:3-18 (in German)]. doi: 10.17886/RKI-GBE-2018-075
- Siegels D, Haufe E, Heinrich L, et al. Status report on the atopic dermatitis registry TREATgermany. Allergol Select. 2021;5:274-86. doi: 10.5414/ALX02262E
- Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69(1):3-16. doi: 10.1111/all.12270
- Kage P, Zarnowski J, Simon JC, Treudler R. Atopic dermatitis and psychosocial comorbidities - What’s new? Allergol Select. 2020;4:86-96. doi: 10.5414/ALX02174E
- Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-51. doi: 10.1016/j.jaad.2013.10.010
- Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390-401. doi: 10.1016/j.jaad.2018.09.035
- Wollenberg A, Werfel T, Ring J, et al. Atopic Dermatitis in Children and Adults – Diagnosis and Treatment. Dtsch Arztebl Int. 2023;120(13):224-34. doi: 10.3238/arztebl.m2023.0011
- Lodén M, Andersson AC, Anderson C, et al. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. Acta Derm Venereol. 2002;82(1):45-7. doi: 10.1080/000155502753600885
- van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2(2):CD012119. doi: 10.1002/14651858.CD012119.pub2
- Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818-23. doi: 10.1016/j.jaci.2014.08.005
- Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):824-30.e6. doi: 10.1016/j.jaci.2014.07.060
- Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904-26. doi: 10.1111/jdv.18429
- van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2(2):CD012119. doi: 10.1002/14651858.CD012119.pub2
- Kawashima M, Hayashi N, Nogita T, et al. The usefulness of moisturizers for maintenance of remission in atopic dermatitis. Jpn J Dermatol. 2007;117:1139-45.
- El-Saber Batiha G, Magdy Beshbishy A, El-Mleeh A, et al. Traditional Uses, Bioactive Chemical Constituents, and Pharmacological and Toxicological Activities of Glycyrrhiza glabra L. (Fabaceae). Biomolecules. 2020;10(3). doi: 10.3390/biom10030352
- Mostafa ES, Maher A, Mostafa DA, et al. A Unique Acylated Flavonol Glycoside from Prunus persica (L.) var. Florida Prince: A New Solid Lipid Nanoparticle Cosmeceutical Formulation for Skincare. Antioxidants (Basel). 2021;10(3). doi: 10.3390/antiox10030436
- Danby SG, Andrew PV, Taylor RN, et al. Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis. Clin Exp Dermatol. 2022;47(6):1154-64. doi: 10.1111/ced.15141
- Zhao G, He F, Wu C, et al. Betaine in Inflammation: Mechanistic Aspects and Applications. Front Immunol. 2018;9:1070. doi: 10.3389/fimmu.2018.01070
- Ebner F, Heller A, Rippke F, Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol. 2002;3(6):427-33. doi: 10.2165/00128071-200203060-00005
Supplementary files
